InMed Q2 Revenue Drops 26% as INM-901 Preclinical Bioavailability Excels
InMed’s BayMedica segment generated $0.8 million in Q2 fiscal 2026 revenue, a 26% decline from $1.1 million, while R&D spending fell to $0.6 million and G&A edged down to $1.6 million. The company reported $7.0 million in cash and short-term investments, extending its runway into Q4 2026, and highlighted robust PK results for INM-901 preclinical studies.
1. Financial Results
For the quarter ended December 31, 2025, InMed’s BayMedica commercial business recorded $0.8 million in revenue, down 26% from $1.1 million due to legislative uncertainties. Research and development expenses decreased to $0.6 million from $0.9 million year-over-year, while general and administrative costs fell slightly to $1.6 million from $1.7 million.
2. INM-901 Preclinical Progress
INM-901, a small-molecule CB1/CB2 agonist targeting neuroinflammation in Alzheimer’s disease, completed first large-animal oral pharmacokinetic studies showing robust bioavailability and anticipated therapeutic systemic exposure over seven days, with no adverse neural or behavioral effects. Next steps include CMC scale-up, dose-ranging in two species, GLP-enabling studies and a pre-IND FDA meeting.
3. INM-089 Development Update
INM-089, an intravitreal injectable candidate for dry age-related macular degeneration, demonstrated significant functional and pathological improvements in preclinical models at doses up to ten times the safety margin. The program is advancing toward GLP-enabling studies and a pre-IND meeting with the FDA.
4. Cash Position and Legislative Risk
As of December 31, 2025, the company held $7.0 million in cash and short-term investments, projected to fund operations into calendar Q4 2026. However, provisions of H.R. 5371 could prohibit key aspects of BayMedica’s cannabinoid inventory if enacted by November 12, 2026, posing a material risk to future revenue.